Although pharmacological treatments for major depressive illness, which afflicts 17% of the population in the USA alone, have been available for over 50 years, the molecular mechanisms underlying the therapeutic response to these agents have remained unresolved. Available medications are known to block the reuptake or breakdown of serotonin, norepinephrine, or both in brain, but elevation of these monoamines, which occurs rapidly (within days), does not explain the time lag of weeks to months that is required for a therapeutic response to antidepressant treatment.
The discovery that long-term antidepressant treatment increases brain-derived neurotrophic factor (BDNF), a major neurotrophin in the brain, has offered an alternative to the monoamine hypothesis of depression and antidepressant response (Duman et al., 1997) . The finding that antidepressants also increase hippocampal neurogenesis extended this work and gave birth to the hypothesis that this cellular form of neuroplasticity in the adult brain is necessary for the behavioral effects of antidepressants (Drew and Hen, 2007; Duman and Monteggia, 2006) . These findings, as well as reports that both BDNF expression and hippocampal neurogenesis are decreased in animal models of depression, have raised several fundamental questions. Are these effects causally related (i.e., does induction of BDNF underlie the increase in neurogenesis) or are they merely coincidental, unrelated responses? Do increased BDNF and hippocampal neurogenesis contribute to the behavioral actions of antidepressants, and conversely, does reduction of these processes contribute to depression? An article by Li et al. in this issue of Neuron (Li et al., 2008) elegantly demonstrates a direct functional link between these two key areas of investigation, highlighting the importance of TrkB and adult neurogenesis in the efficacy of antidepressants in rodent behavioral models.
One fundamental question of the current study concerns the cellular localization of TrkB and how this influences antidepressant regulation of adult neurogenesis. Toward this end the Parada laboratory developed and utilized stateof-the-art cell isolation and labeling approaches in combination with sophisticated TrkB mutant mouse models that take advantage of the expression of cellspecific antigens. In the adult hippocampus, neural progenitor cells (NPCs) located in the subgranular zone proliferate and give rise to immature neurons that migrate into the granule cell layer, where they differentiate and mature (see Figure 1 ) (Zhao et al., 2008) . These cells express the markers Nestin and glial-fibrillary acidic protein (GFAP). Li and colleagues use fluorescence-activated cell sorting (FACS) to isolate NPCs from Nestin-GFP transgenic mice and show that adult hippocampal progenitor cells express TrkB as well as BDNF. They also demonstrate that TrkB is expressed on dividing progenitor cells, as determined by colocalization with a cell-cycle marker, as well as on immature and mature neurons in brain sections.
Because there are two major types of NPCs, slowly dividing/quiescent neural progenitors (QNP) and rapidly amplifying neural progenitors (ANP), both of which express Nestin, a remaining issue is whether one or both cell types express TrkB. This is important to define because one study has reported that chronic administration of the antidepressant fluoxetine or Prozac stimulates the proliferation of ANP, but not QNP, cells (Encinas et al., 2006) , while another study has found that electoconvulsive seizure, which is still the most efficacious treatment for depression, increases both types of NPCs (Nishida et al., 2008) .
To directly test the functional significance of TrkB expressed in NPCs, Li and colleagues generated trkB gene deletion mutants in a cell-specific manner. Conditional mutants were generated by crossing mice harboring the trkB floxed allele with transgenic mice expressing Cre recombinase under the human GFAP (hGFAP) promoter. Because TrkB is also expressed on mature neurons, deletion of TrkB in this population of cells was also generated by crossing these mice with another line where Cre expression is under the control of the promoter for Synapsin I (Syn), a marker of mature neurons. At a gross structural level, the TrkB hGFAP , but not the TrkB Syn , deletion mutants exhibited a reduction in the volume of the hippocampus as early as postnatal day 10. This effect was due to a reduction in the number of granule cells, and was not observed in other brain regions such as the striatum. These findings highlight the importance of NPC-expressed TrkB on early postnatal development of the hippocampus.
Direct analysis of adult hippocampal neurogenesis revealed that the TrkB than 50%) reduction in basal levels of cell proliferation that was not observed in the TrkB Syn deletion mutants. BDNF stimulation of neurosphere size was also blocked in cultures isolated from TrkB hGFAP mice. Importantly, the ability of chronic administration of either a serotonin selective reuptake inhibitor (fluoxetine) or a tricyclic antidepressant (imipramine) to increase cell proliferation was completely blocked in the TrkB hGFAP mice. In contrast, there was no significant effect in the TrkB Syn mice. In addition, the induction of cell proliferation by exercise, which also produces antidepressant effects in rodent models and in humans, was also blocked in the TrkB hGFAP mice.
Despite previous studies demonstrating that BDNF infusions increase neurogenesis and that induction of neurogenesis is blocked in BDNF heterozygous deletion mutants, there have also been conflicting reports (Drew and Hen, 2007; Duman and Monteggia, 2006; Monteggia et al., 2007) . In particular, one study has reported that expression of a dominantnegative mutant of TrkB in transgenic mice did not influence basal or antidepressant-induced cell proliferation, although a decrease in the survival of newborn neurons was observed (Sairanen et al., 2005) . This discrepancy is likely due to expression of the TrkB dominantnegative mutant in neurons, under the control of the Thy1 promoter. Given this finding, it would be interesting to determine if survival of new neurons is decreased in the TrkB Syn mutant mice. These inconsistencies and discrepancies underscore the significance of the current study, as it provides the first evidence that the neurogenic actions of BDNF and antidepressants are mediated by TrkB receptors located on NPCs.
Another key aspect of these current data is the functional link between BDNF-TrkB, neurogenesis, and the behavioral actions of antidepressant. Previous studies have reported that the behavioral responses to antidepressants are blocked in BDNF deletion mutant mice (Duman and Monteggia, 2006) . In addition, there is strong evidence that blockade of adult neurogenesis by cellcycle inhibitors or irradiation blocks the behavioral actions of antidepressants, though there are some exceptions (Drew and Hen, 2007) . The results of the current study directly link BDNF-TrkB signaling, adult neurogenesis, and antidepressantregulated behaviors: the effects of fluoxetine or imipramine, as well as exercise in two different behavioral models, the novelty-suppressed feeding test (NSFT) and the tail suspension test (TST), are completely blocked in the TrkB hGFAP mice, but once again not in the TrkB Syn deletion mutants. The significance of these results lies not only in the connection between antidepressant behavioral responses and TrkB, but also between these responses and adult neurogenesis. Nevertheless, there are also some limitations of these behavioral paradigms. First, the TST is a behavioral despair model that was designed as a rapid screen for antidepressants, which increase the amount of time of a mouse will struggle before becoming immobile or giving up. Although the current study tests the influence of long-term antidepressant treatment, the fact remains that this test responds to acute drug administration, limiting its clinical relevance given the time lag for a therapeutic response to antidepressant treatment. Second, the NSFT is actually a model of anxiety, but the response is dependent on chronic antidepressant treatment, which decreases the latency to feed in an open field. The impact of the current study will be further increased by analysis of TrkB deletion in other behavioral tests, such as chronic mild stress-induced anhedonia (stress decreases sucrose consumption) or social defeat (exposure to dominant resident decreases social interaction), both of which measure core symptoms of depression that are reversed by long-term antidepressant administration.
Even though this study of the TrkB hGFAP and TrkB Syn mice indicates that the neurogenic and behavioral actions of antidepressants are mediated by direct effects on NPCs, the early postnatal developmental changes in the hippocampus of the TrkB hGFAP mice raise the possibility that the effects are not directly related to TrkB in adult NPCs. Specifically, the decrease in the number of granule cells and NPCs could account for the neurogenic and behavioral effects observed in the adult animals. To address this issue, the Parada laboratory generated a third line of TrkB deletion mutant mice using a tamoxifen-inducible form of Cre recombinase under the Nestin promoter (TrkB   Nestin   ) . This powerful, complementary line allows inducible deletion of TrkB in the NPCs, both QNP and ANP, but There was also a decrease in basal neurogenesis levels in the TrkB Nestin mice, but this effect was more subtle (30%) than in the TrkB hGFAP mice, presumably due to the lack of developmental effects. Notably, the behavioral effects of antidepressant treatment and exercise were also completely blocked in the TrkB Nestin mice.
As is often the case, elegant studies such as the current report raise additional questions. One issue that remains unresolved is the source of BDNF that is regulated by antidepressant treatment or exercise. The current study presents evidence that BDNF, like TrkB, comes from the NPCs. BDNF is expressed in the FACS-isolated NPCs, and BDNF hGFAP deletion mutant mice also display a reduction in the volume of dentate gyrus graule cell layer, as seen in the TrkB hGFAP mice (although additional studies are needed to determine if there is a decrease in neurogenesis in the BDNF hGFAP mice). The authors suggest that these results support a cell-autonomous effect of BDNFTrkB signaling in the actions of antidepressant treatment and exercise on NPC proliferation (see Figure 1) . However, it is also possible that in the adult animal, BDNF is released from mature neurons or even glia in response to antidepressant treatment or exercise. Indeed, previous studies have demonstrated that these treatments induce BDNF expression in mature neurons in the granule cell layer (Duman and Monteggia, 2006) . Additional studies using cell-specific deletion approaches similar to those used for conditional deletion of TrkB will be required to further elucidate the source of BDNF. Another, related question is which monoamine receptor subtype or subtypes mediate antidepressant stimulation of BDNF-TrkB signaling.
Another question raised by the current study, as well as previous reports, is whether reductions in BDNF-TrkB signaling and neurogenesis contribute to a depressive-like behavioral phenotype. In the current study, significant reductions in basal neurogenesis in the TrkB hGFAP and TrkB Nestin mice were not accompanied by increased immobility in the TST or latency in the NSFT. Similarly, ablation of cell proliferation by focused irradiation blocks antidepressant induction of neurogenesis and behavior, but does not result in depressive-like behaviors (Airan et al., 2007; Santarelli et al., 2003) . Together these findings indicate that while induction of BDNF-TrkB signaling and neurogenesis is required for the behavioral actions of antidepressants, reductions of these processes are not sufficient to produce depressive-like behaviors. However, a note of caution is necessary as these behavioral tests, particularly the TST, were designed to screen for antidepressant responses, not as models of depression. Another possibility is that there may be a gene 3 environment interaction (i.e., prior exposure to stress could lead to a behavioral vulnerability in the TrkB hGFAP or TrkB Nestin mice), as reported for BDNF mutant mice and for a functional BDNF polymorphism in humans Kim et al., 2007) . In addition to BDNF-TrkB, antidepressant treatments also increase the expression of other growth factors (Duman and Monteggia, 2006) , and a recent study reported that one of these, vascular endothelial growth factor (VEGF), is also required for the neurogenic and behavioral actions of antidepressants (WarnerSchmidt and Duman, 2007) . These findings suggest that there may be redundant or overlapping growth factor signaling pathways that underlie the induction of neurogenesis and behavioral responses to antidepressants, and raise still additional questions. How do these trophic factors interact? Do they share the same intracellular signaling pathways? Or does signaling through one factor (e.g., BDNFTrkB) influence expression, trafficking, and/or signaling of other receptors?
Despite these issues, the current study provides a major advance in our understanding of the cellular actions of antidepressant treatment by demonstrating that TrkB on neural progenitors in the hippocampus is a common molecular target for both chemical agents and exercise. With further advances in our knowledge of the cellular mechanisms that regulate neurogenesis, and with the development of tools targeting these mechanisms, studies of these ''old'' drugs that were once thought to merely counteract chemical imbalances will continue to surprise us and lead to discoveries that can be targeted for novel treatments for mood disorders.
